Adtralza (tralokinumab-ldrm)
Condition : New
0
From UAE
To United States
in 5-10 days
Description
Adtralza, with the active ingredient Tralokinumab-ldrm, is a monoclonal antibody that is primarily used for the treatment of moderate to severe atopic dermatitis (eczema) in adults. This biologic therapy specifically targets and neutralizes interleukin-13 (IL-13), a key cytokine involved in the inflammatory response associated with atopic dermatitis. It is available as a subcutaneous injection and is typically prescribed when topical therapies are insufficient or inappropriate.
How Adtralza (Tralokinumab-ldrm) Works
Adtralza works by binding to interleukin-13 (IL-13), a pro-inflammatory cytokine that plays a central role in the pathophysiology of atopic dermatitis. IL-13 is involved in triggering the inflammatory process in the skin, leading to symptoms such as redness, itching, and swelling. By inhibiting IL-13, Adtralza helps to reduce these inflammatory responses, thus alleviating the signs and symptoms of eczema. Unlike conventional therapies that generally suppress the immune system broadly, Adtralza specifically targets the IL-13 pathway, allowing for a more focused treatment of atopic dermatitis while minimizing systemic side effects.Indications
Adtralza is indicated for the following:- Moderate to Severe Atopic Dermatitis (Eczema): Adtralza is used to treat adults with moderate to severe atopic dermatitis whose condition is not adequately controlled with topical treatments or when such treatments are not advisable. It is usually prescribed as part of a comprehensive skincare plan that may include topical therapies, emollients, and other supportive measures.
Side Effects
Adtralza can cause side effects, although not everyone experiences them. The most common side effects include:- Injection site reactions (pain, redness, swelling)
- Upper respiratory infections
- Headache
- Conjunctivitis (pink eye)
- Eye irritation
- Hypersensitivity reactions (rash, hives, itching, difficulty breathing)
- Serious infections due to immune suppression
- Worsening of eye problems (if already present)
Contraindications
Adtralza should not be used in certain situations where it could cause harm. It is contraindicated in:- Patients with known hypersensitivity to Tralokinumab or any of the ingredients in Adtralza
- Active infections, especially those that are untreated or severe
- Individuals with a compromised immune system that may be unable to handle reduced IL-13 activity
- Pregnant or breastfeeding women, unless advised by a healthcare provider, as the safety of the drug during pregnancy and breastfeeding has not been established
Price of Adtralza (Tralokinumab-ldrm) in Different Countries
The price of Adtralza can vary significantly depending on the country and healthcare system. Below is a table displaying the approximate price of Adtralza in different countries with references to the sources:Country | Price (per injection) | Source |
---|---|---|
United States | $2,800.00 | GoodRx |
United Kingdom | £1,900.00 | NICE BNF |
Canada | CAD 3,200.00 | DrugBank |
Australia | $4,200.00 AUD | PBS Australia |
India | $1,500.00 | 1mg |
Top 5 Global Brands of Tralokinumab-ldrm
Adtralza is one of the leading brands for Tralokinumab, but there are other prominent biologic treatments targeting similar pathways. Below are the top five global brands:- Adtralza (Tralokinumab) by LEO Pharma
- Dupixent (Dupilumab) by Sanofi and Regeneron
- Fasenra (Benralizumab) by AstraZeneca
- Skyrizi (Risankizumab) by AbbVie
- Ilumya (Tildrakizumab) by Sun Pharma